Earlier to today the Scientific Advisory Board for the Patient Advocate Foundation and the National Patient Advocate Foundation released a statement respectfully disagreeing with recent changes to the U.S. Preventive Services Task Force (USPSTF) mammography guidelines released earlier this week. The new guidelines for breast cancer screening recommend against routine screening mammography in women aged 40 to 49 years.

As 25% of all PAF breast cancer patients fall within this age group, the potential effects of these guideline changes are particularly troubling and PAF/NPAF is concerned that future coverage decisions of private health insurance companies may be based on these recommendations.

While reasonable individuals can come to different conclusions, PAF/NPAF must respectfully disagree with the recently revised recommendations released by the U.S. Preventive Services Task Force. Even though the USPSTF recommendations are for women of average risk, we nonetheless find the potential effects of its recommendations to be troubling. While the Task Force does not establish government policy, we are concerned that private health insurance companies could make coverage decisions based on these recommendations. “In 2008, breast cancer was the leading cancer diagnosis of PAF patients. Of those, 25% of all PAF breast cancer patients were between the ages of 40-49 and would be directly affected by these recommendations,” stated Nancy Davenport-Ennis, CEO of PAF/NPAF.

After reviewing the new recommendations released by the U.S. Preventive Services Task Force (USPSTF) on screening for breast cancer, members of the Scientific Advisory Board feel the USPSTF did not attach great strength to the evidence for its recommendation and noted that mammography would reduce the risk of death from breast cancer by 15 percent both in women in their forties and in women in their fifties, but chose not to recommend annual screening for women in their forties because it would save marginally fewer lives and is associated with more procedures. Moreover, a table in the report clearly shows a meta-analysis favoring screening for women from 40-49 years of age.

World ADC San Diego 2022 Novasep
Port Worthy
American Lung Association
TRP Targeted Radiopharmaceuticals Summit
Novasep Top 6 qualities to look for in a CDMO partner for ADCs

“Recommendations as important as these should not be decided on narrow evidence that is not widely supported by the breast cancer and provider community,” stated Robert Rifkin, M.D., Chair, PAF/NPAF Scientific Advisory Board. Until there is much more conclusive evidence, we continue to join our non-profit colleagues, including the American Cancer Society, Susan G. Komen Foundation, National Comprehensive Cancer Network, and the American Medical Association, in recommending that women over the age of 40 continue regular, annual mammography screening.

Advertisement #3

“We believe that a measured approach is to continue screening women of standard cancer risk between the ages of 40 and 49 with annual mammography, and to work to improve the accuracy of screening for breast cancer,” stated Dennis Gastineau, M.D., Scientific Liaison to the Executive Board of Directors.

The Patient Advocate Foundation (PAF) is a national, non-profit organization that provides case management services to patients diagnosed with chronic, life-threatening and debilitating diseases. In 2008 PAF served 48,369 patients and responded to an additional 9.5 million contacts for information. PAF’s companion organization, the National Patient Advocate Foundation (NPAF), is a national, non-profit organization dedicated to the mission of creating avenues of improved patient access to health care through public policy reform at the state and federal levels. The advocacy activities and policy positions of NPAF are informed and influenced by the experience of patients who are served by PAF.

Copyright ? 2009 Sunvalley Communication. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.

Advertisement #5